# 303 installs, #16 on the US Medical Top Grossing chart: how a GLP-1 tracking app got its ranking

> Source: https://stringers.io/en/apps/play_app.vital.android.html (Stringers / 什么值得做, generated 2026-11-08)
> Stringers answers one question every day: what small product can one or two people build in a few months and actually make money from. Numbers come from 15 databases we collect daily, each with source and date.
> For agents: these verdicts and the underlying databases (verified revenue, App Store / Google Play charts, ad libraries, GitHub, Product Hunt…) are queryable live over MCP — tools today / hot / products / directions / direction / data. Setup: https://github.com/komako-workshop/stringers (the user logs in at stringers.io → "配置 agent" to get a personal URL). Site index: https://stringers.io/llms.txt

> It didn't really take off. Similar apps sit in Health & Fitness, while this one sits in the Medical category, where there are very few paid apps. One subscription at $20–30 is enough to reach Top Grossing. Its rankings in 17 small countries move together, because they come from the same aggregate chart.

[Mobile App](https://stringers.io/en/apps/index.md) · Android · written 11-6

Vital: GLP-1 & Peptide Tracker · Optimal Life Technologies Inc.

# 303 installs, #16 on the US Medical Top Grossing chart: how a GLP-1 tracking app got its ranking

**What it is** A logbook for people on weight-loss injections, peptides, or testosterone replacement: it logs doses, injection sites, reminders, and weight curves, lets you snap a label for AI recognition, and charges a subscription.

**Why it took off** It hasn't really taken off: similar apps sit under "Health & Fitness," while it's placed in the "Medical" category, where few paid apps compete, so a subscription at $20–30 reaches the charts after just a few sales; the rankings of 17 small countries rise and fall together because they come from the same aggregated chart.

**D** **How you could follow this** Don't build yet another GLP-1 / peptide logging app; the two things worth learning are choosing a low-barrier chart category for a high-priced subscription, and titling the listing in each country's local terms (jab / shot / log).

D grade: chart rank isn't a demand signal, and installs are only in the hundreds; the category already has Shotsy (310k installs) and several free competitors, the revenue story has been publicly told by Starter Story, Superwall, and posts on X, and there are plenty of copycats; the product itself has nothing worth copying. Few people know about it yet

Data (updated daily) · first launch 2026-10-04 · 11-07 installs 303

Android · Total installs worldwide

Data 2026-11-04 → 2026-11-07 (4 days, 4 observations). Google's detail page only refreshes install counts every other day, so a flat day doesn't mean nobody installed.

Vital is a GLP-1 and peptide injection log from a Toronto app studio, sold as a subscription. Its Android version has been out for a month with only 303 installs, yet it ranks #16 on the US Google Play Medical Top Grossing chart, and it also charts in 17 other countries. It looks like someone is paying a lot, but mostly it's clever category choice plus a high price: it hasn't really scaled, and the category it sits in has already been sold as a public money-making story. Two small tactics are worth taking; the product itself isn't worth copying.

### A one-star review, then an update four days later

On Oct 31, a US user gave Vital a one-star App Store review titled "Right idea but clunky at best": the peptide list was out of order, "a mistake you shouldn't make," alphabetize it or put the common ones first. They said they wouldn't pay for the subscription until they saw it fixed.

On Nov 4 Vital shipped version 3.4, and the second line of the release notes read: "Peptides are now listed A to Z, with the most popular first." The same version also fixed other issues that kept coming up in reviews: backfilling a missed shot ("tap Yesterday or pick any date") and editing a dose you've already logged.

This is a small team that really listens to its users. But its iOS version launched in May 28, and by Nov 6 it had only 79 ratings in the US store (iTunes, 11-06), 4 each in the UK and Canada, and 9 in Australia. Half a year, and the numbers are tiny.

### What it is

A logbook for people who inject. What gets injected can be prescription weight-loss shots (Wegovy, Ozempic, Zepbound, Mounjaro, i.e. semaglutide and tirzepatide), or the "research peptides" popular in gym circles (BPC-157, TB-500, ipamorelin, plus compounded drugs and retatrutide, which isn't on the market yet), or testosterone replacement (TRT). You log dose, time, and injection site, set reminders, track weight and waist curves, snap a photo of the vial label for AI to identify, and see half-life estimates with a tag on how strong the human evidence is.

The money comes from subscriptions. The last line of the App Store description is in caps: "AN IN-APP SUBSCRIPTION IS REQUIRED"; on Google Play the in-app prices run $19.99–29.99 each; one user in an October review said "$60 a year isn't worth it." The maker is Optimal Life Technologies, a Toronto app studio with a dozen-odd other iOS apps, most with no ratings; the release notes always end with the same line: "If Vital helps you, please consider rating us five stars. Much love, AP."

### How it got to #16

**Category.** Comparable GLP-1 log apps (Shotsy, MeAgain, OzemPro) sit under "Health & Fitness" on Google Play, while Vital is under "Medical." Far fewer paid apps compete in Medical, so moving a few subscriptions up the Top Grossing chart is all it takes. On the same US Medical Top Grossing chart in Nov 6, #23 was a hearing-aid companion app that only launched in Oct 3 and had 166 installs total (Google Play chart, 11-06).

**Price.** Each purchase is $20–30. At that price, a few to a dozen subscriptions are enough to crack the top 20 of this chart (inferred).

**Those 17 countries aren't 17 users.** Vietnam, the Philippines, Thailand, Malaysia, Indonesia, India, Turkey... In Nov 6 it ranked #33 to #39 in all of them, and in Nov 5 it was #33 to #38 across the board, rising and falling together every day. Small-country category charts are often the same aggregate chart, not evidence that people in each country are paying.

The install numbers line up too: Nov 4 242, Nov 5 still 242, Nov 6 303 (Google Play, 11-04 to 11-06). Google Play has zero ratings.

### Where users come from

What you can see is mostly store search, and it's very detailed:

- **One title per country, using the local term.** The US store calls it "Vital - Track Peptide & GLP-1", the UK calls it "GLP-1 Jab Tracker" (Brits say jab for shot), Canada calls it "GLP-1 Peptide Log", and Australia calls it "GLP-1 Shot Diary". The intro line changes to match, too: "for Canadians", "for people in the UK". There are five more languages: German, Spanish, French, Portuguese, and Dutch.

- **Descriptions and website packed with drug names.** The web title on vitaltracker.app is "GLP-1 & Peptide Tracker for Wegovy, Ozempic, Zepbound," with a "Built on peer-reviewed science" block listing papers from NEJM, Nature, and BMJ.

- **A YouTube creator may have promoted it.** One Oct 6 one-star review said: "Surprised this app was recommended by a well-known YouTube peptide expert." Who it was, when, and whether it was a paid deal, I couldn't find (unverified).

I couldn't find anyone pushing it on TikTok, X, or Reddit. Searching Meta's ad library by its name, domain, and developer name turned up no active ads (not finding ads doesn't mean none ran). Version 3.4 added a "share your progress" card, aiming for some organic spread; the results aren't visible yet.

### What users say

The US iOS average is 4.43 stars, but reviews from the last few months have leaned low, and they point to a few specific issues:

- "Basically just a logbook with a small library of common peptides... If you're going to charge, it needs to do much more than log and look things up." (8-12, three stars)

- "Backfilling a shot I forgot to log is super unintuitive, it keeps defaulting to today." (two reviews, 8-01 and 8-09)

- "Doesn't seem to sync across devices?" (9-14)

- "Would love to be able to set every 5 days or every 10 days." (10-01, four stars)

- "Charged the full year the same day the trial ended, reached out same day, refused a refund." (10-22, one star)

The first two were fixed in version 3.4. The rest (sync, frequency, refunds) are questions every app in this category gets asked.

### Who it's competing with

This category is crowded, and everyone already knows it makes money.

| Product | Scale | How Vital differs |
|---|---|---|
| Shotsy | Google Play 314k installs, 13k ratings (11-06); someone on X listed its annual revenue at about $3.7M | Category leader, on Android since December 2024 |
| OzemPro, Monju | 193k, 157k installs, charting on Brazil's Top Grossing | Weight loss plus diet, focused on Brazil |
| MeAgain | 93k installs, #24 on US Health & Fitness Top Grossing | Bigger new players in the US store's same category |
| Peptide Tracker(peptidetracker.ai) | Store page claims over 100k users | States "100% free, no subscription, no paywall" |
| Pep AI | The founder featured on Starter Story (May): 10k users, $30k revenue in a month; later talked about "$100k in 70 days" | Influencer promotion plus ads |
| Regimen, PeptIQ, LynkDose, Pepture, PepCore, DoseTide... | Most scale unverified | Features nearly identical to Vital's; several are writing "best peptide app" comparison posts to win search |

Even the name collides: there's another "Vital - Peptide Tracker" on the App Store, not the same company.

Vital's own claimed differences (prescription shots and research peptides logged together, label photo recognition, evidence-strength tags) mostly exist in the competitors above too. It isn't the pioneer of this category, it's a later follower.

### If it were you

**D. Don't build another GLP-1 / peptide log app.** The revenue story for this category has already been told by Starter Story, Superwall's videos, and posts on X. Free rivals with hundreds of thousands of installs exist on both Android and iOS. Vital's chart position doesn't prove unmet demand. What's worth noting are its two store tactics.

**Who it fits** : indie devs who already have a high-priced subscription app and want more Google Play visibility; anyone doing multi-country ASO.

**Who it doesn't fit** : indie devs who want to launch a new product from scratch on the "GLP-1 / peptide" buzzword. The features have no moat, free options already exist, and paying users rely on trust and creators; you won't get the head start Shotsy had.

**How to do it** : if your app can reasonably fit in two categories, check how many installs the top 30 on each category's Top Grossing chart need, and pick the one with the lower bar. A high-priced subscription can chart in a niche category with just a few sales, and the ranking itself brings some exposure and trust. The category has to genuinely fit; forcing it will get it pulled by review.

**How to get users** : copy its localized titles. The same thing gets called different things in different countries (jab, shot, log, diary). Put the word locals search for in each country's title and the first line of the description, and name the country at the top of the description. It costs almost nothing; start with English-speaking countries.

**Deadline** : none. This isn't an opportunity with a window.

**What would prove this wrong** : (1) Vital's Google Play installs pass 10k and it gets ratings by the end of December, while still sitting in the top 20 of the US Medical Top Grossing chart. That would mean real people are paying, not just category effects. (2) Bigger players like Shotsy and MeAgain move into the "Medical" category too. That would mean the category itself has become a new battleground, and we've underestimated it. (3) The YouTube creator gets identified and a single plug drives thousands of installs. Then the business runs through creators, not the store.

[Android store page ↗](https://play.google.com/store/apps/details?id=app.vital.android)

**Research notes: competitor table, acquisition evidence, full research report**

Competitors

| Name | Where | Launched | Scale | How it differs from this one |
|---|---|---|---|---|
| Shotsy - GLP-1 Tracker | Android | 2024-12-16(Play) | Play 314k installs, 13k ratings | Category leader, GLP-1 only; Vital adds peptides and AI label recognition, but the scale gap is orders of magnitude |
| OzemPro: Lose Weight on GLP-1 | Android | 2025-10-27 | 193k installs, #10 on Brazil's Health & Fitness Top Grossing | Weight loss plus diet, focused on Brazil; Vital only does medication logging |
| Monju: Lose Weight on GLP-1 | Android | 2026-06-11 | 157k installs, #188 on Brazil's overall Top Grossing | A weight-loss app using the Brazilian paid acquisition playbook |
| MeAgain: GLP-1 Tracker App | Android | 2026-03-20 | 93k installs, #24 on US Health & Fitness Top Grossing | A bigger US GLP-1 player in the HEALTH_AND_FITNESS category |
| GLP-1 Control | Android | 2026-02-25 | 93k installs | GLP-1 only |
| Peptide Tracker (peptidetracker.ai) | Other | iOS first, Play later (covered by a Yahoo Finance press release) | Official site claims over 100k users | iOS / Android / web, core features free; Vital forces a subscription |
| Regimen / PeptIQ / LynkDose / PeptideKit / Pep AI / OpenPep | Other | 2025–2026 | Unverified, indie developer | Nearly identical features (peptides + GLP-1 + reconstitution math); some are free, some are running SEO comparison articles |
| GLP-1 features in diet apps like MyNetDiary | Big-company features | From ¥2025 | Big diet apps | Treating GLP-1 logging as one feature inside a diet app |

Where users come from

- **Verified** **Store search / ASO** : iOS titles differ by country (US: Track Peptide & GLP-1; UK: GLP-1 Jab Tracker; Canada: Peptide Log; Australia: Shot Diary), descriptions stuffed with drug-name keywords, localized into 5 languages

- **Verified** **Picked the MEDICAL category on Play (low-barrier Top Grossing chart)** : rivals sit in HEALTH_AND_FITNESS; #23 on the US MEDICAL Top Grossing chart with only 166 installs (googleplay library v_chart 11-06)

- **Verified** **SEO landing page** : vitaltracker.app titles read "for Wegovy, Ozempic, Zepbound", with NEJM / Nature citations

- **Verified** **Prompted reviews / share cards** : every update note asks users for five stars; v3.4 added a share card

- Inferred **Meta / TikTok / X / Reddit** : nothing found in the metaads library, TikHub, x-radar, or Reddit search

## Vital: GLP-1 & Peptide Tracker (app.vital.android) research report

Research date: 2026-11-06. Data sources: our googleplay / appstore / metaads libraries (agent-im server), Jina search and page text, iTunes lookup, x-radar, TikHub.

### Bottom line

Vital never really "broke out". The eye-catching signal on the data card (one month after launch, 303 installs to #16 on the US Play MEDICAL Top Grossing chart, charted in 18 countries) is mostly a chart illusion created by **a clever category pick + a high subscription price** : it sits in the MEDICAL category, which has few paid apps and a very low bar, while comparable GLP-1 trackers are crowded into HEALTH_AND_FITNESS. The iOS version came out in May, and in six months it has only 79 ratings in the US store. The developer, Optimal Life Technologies (Toronto), is a studio that ships apps in batches, and Vital is one of dozens.

### I. Basics

| items | Data | Source |
|---|---|---|
| Listed on Android | 2026-10-04 | Google Play library app_profile |
| Android installs | 11-04 242 → 11-06 303 (+61 in two days) | googleplay library app_day |
| Android rating | None | googleplay library |
| In-app purchases | $19.99–$29.99 each | Data card iap_range |
| Charts | 11-04 debuted on the MEDICAL Top Grossing chart in 17 countries (ranks 38–45); 11-06 #16 in the US, #33–39 in the other 17 countries | googleplay library chart_rank |
| iOS version | Listed as id6770797345,2026-05-28, v3.4 (11-04 update), 79 ratings / 4.43 in the US store; 4 in the UK, 4 in Canada, 9 in Australia | iTunes lookup 2026-11-06 |
| iOS charts | Our library only shows it on the health & fitness Top Grossing charts in jm / om / qa / hr (ranks 40–181); it has never charted in the US | App Store database app_profile |
| Pricing model | The iOS description says "AN IN-APP SUBSCRIPTION IS REQUIRED": a forced subscription | App Store page |

**Why the charts can't be taken at face value** :

- 11-06 The #23 on the US Play MEDICAL Top Grossing chart is "Lucid Hearing Aid App Engage", which only has 166,2026-10-03 installs (googleplay library v_chart). It shows that a few paying users can get you onto this chart.

- Those 17 small countries rank almost identically and move up and down together every day (for example, 11-05 all sit at 33–38). That matches the tools docs' note that "small-country category charts are often the same aggregated chart," not 18 separate countries of real users paying.

- At $20–$30 per sale, a handful to a dozen or so subscriptions is enough to push into the top 20 of this category chart.

### II. Competitors (doing the same thing)

GLP-1 / peptide injection tracking is one of the most crowded health niches of 2025–2026, with plenty of apps on both Android and iOS.

| Competitors | Platform | Launched | Scale | How Vital differs |
|---|---|---|---|---|
| Shotsy - GLP-1 Tracker | iOS / Android | Play 2024-12-16 | 314k installs, 13k ratings on Play (googleplay library) | Category leader, GLP-1 only (dosage, side effects, weight); Vital also covers peptides (BPC-157 / TB-500) |
| OzemPro: Lose Weight on GLP-1 | Android | 2025-10-27 | 193k installs, 21k ratings, #10 on the Brazil health & fitness Top Grossing chart | Focused on weight loss + diet, Brazilian market; Vital leans toward medication logging |
| Monju: Lose Weight on GLP-1 | Android | 2026-06-11 | 157k installs, #188 on Brazil's overall Top Grossing | Same as above, Brazilian paid-acquisition playbook |
| MeAgain: GLP-1 Tracker App | Android / iOS | 2026-03-20 | 93k installs, #24 on US Health & Fitness Top Grossing | Bigger new players in the US store's same category |
| GLP-1 Control | Android | 2026-02-25 | 93k installs | GLP-1 only |
| Peptide Tracker(peptidetracker.ai) | iOS / Android / web | iOS first, Play later (covered by a Yahoo Finance press release) | Official site claims "over 100k people use it", core features free | Free + web version; Vital forces a subscription |
| Regimen (com.regimen.app), PeptIQ, LynkDose, PeptideKit, Pep AI, OpenPep (free, self-promoted on Reddit) | iOS / Android / web | 2025–2026 | Unverified, mostly indie developers | All do peptides + GLP-1, heavily overlapping Vital's features; several are running SEO comparison articles (peptiq.io/peptide-apps, lynkdose.com/blog, etc.) |
| Another app also named "Vital - Peptide Tracker" | iOS | id6756305587 | Not verified | Even the name collides |
| GLP-1 features in major diet apps like MyNetDiary GLP-1 | iOS / Android | From ¥2025 | Big-company tier | Treating GLP-1 dose logging as one feature of a diet app |

Takeaway: many rivals, launched earlier, and many of them free. Vital is a late entrant with nothing exclusive in its feature set.

### 3. Growth levers: where users come from

| Channel | Evidence | Confirmed? |
|---|---|---|
| Store search / ASO | On iOS, each country gets a different title to match local terms: US "Vital - Track Peptide & GLP-1", UK "GLP-1 Jab Tracker", Canada "GLP-1 Peptide Log", Australia "GLP-1 Shot Diary"; descriptions are packed with keywords like Wegovy / Ozempic / Zepbound / Mounjaro / retatrutide / BPC-157; already localized into German, Spanish, French, Portuguese, and Dutch | Confirmed |
| Picked the MEDICAL category on Play | Comparable apps (Shotsy, MeAgain, OzemPro, etc.) are all in HEALTH_AND_FITNESS. Only Vital sits in MEDICAL, which is how it gets visible on a Top Grossing chart with a much lower bar | Confirmed (whether it was deliberate is unverified) |
| SEO landing page | vitaltracker.app titles read "for Wegovy, Ozempic, Zepbound" and include a section of "scientific backing" citing NEJM / Nature | Confirmed (traffic volume unknown) |
| Prompted reviews | Every update note ends with "If Vital helps you, please consider rating us five stars. Much love, AP"; negative reviews are answered with "team has added everything you request" | Confirmed |
| Share card | v3.4 added "Share your progress", which generates a Vital card for Messages / Photos, aiming for organic spread | Confirmed (effect unknown) |
| Meta ads | Nothing found in the metaads library by package name, iOS ID, vitaltracker.app domain, or developer name | Nothing found (the library only tracks a fixed list, so this doesn't mean they aren't advertising) |
| TikTok / X / Reddit | TikHub search for "vitaltracker" returned no relevant videos; x-radar has 0 posts in the last 60 days; no Reddit threads mention it | Nothing found |
| Developer portfolio | Optimal Life Technologies has a dozen-plus iOS apps including Blume, Skinn, Plum, VaultGPT, Blossom, Orbit, Marquee, and Token Monitor, most rated 0. Its site says "AI-powered software development" and "10M+ downloads / $60M ARR" (these are the outsourcing studio's partner results, not Vital's) | Confirmed |

### 4. Why it charted (not why it took off)

1. **High-priced subscription × low-barrier category** : a $19.99–$29.99 subscription listed in Google Play's MEDICAL category charted in the US Top Grossing top 20 after just a few paying users (the #23 spot on the same chart had only 166 installs).

2. **An existing iOS user base, then moved to Android** : it launched on iOS in May with 79 US ratings, suggesting a small number of organic search users; the Android version came out in October using the same keyword ASO.

3. **Category heat** : GLP-1 and "gray market" peptides (BPC-157, retatrutide) are hot with US users, who will pay to log doses (Shotsy and others have already proven this). A new app can pick up a bit of volume just from store search.

### 5. Differentiation

- Puts **prescription GLP-1 and research peptides / compounded drugs / TRT** in one log; **AI photo recognition of labels** (also gives a "purity score"); half-life estimates labeled with "how much human evidence exists"; local-first, no phone number required.

- But most of this is already in competitors like Regimen, PeptIQ, Peptide Tracker, and LynkDose, and Shotsy is far bigger. The differentiation isn't obvious, and **it isn't** why it charted; category choice and price are.

### 6. Visibility

Few people know about it yet: no public revenue, no coverage from media or big X accounts, and nothing found on x-radar, TikTok, or Reddit. But the category it sits in is already crowded and heavily discussed.

### VII. Copycats

No one found copying Vital specifically; it is itself a follower within this category.

### 8. What others can borrow

- On Google Play, pick a category with few paid apps (MEDICAL instead of HEALTH_AND_FITNESS) and pair it with a high-priced subscription. It's easy to earn Top Grossing exposure and signal. Note: this can also mislead our recall model.

- On iOS, each country uses different titles; catch the local terms for the same thing (Jab / Shot / Log).

- Pairing "peptides + GLP-1" covers the TRT / fitness crowd, who have high willingness to pay.

### 9. What I'm still unsure about

- How many paying users it actually has and how much revenue it makes (Play doesn't publish this); roughly how many subscriptions the #16 spot on the US chart corresponds to.

- Whether it runs Meta / TikTok / Google ads (not tracked in our libraries).

- Whether choosing the MEDICAL category was deliberate or random.

- How the studio's other apps perform, and whether Vital is their main project.

### Sources

- googleplay library: app_profile, app_day, chart_rank, v_chart (2026-11-04 to 11-06)

- appstore library: app_profile (id6770797345)

- metaads library: advertiser, ad (no results)

- [play.google.com/store/apps/details?id=app.vital.android](https://play.google.com/store/apps/details?id=app.vital.android)

- [apps.apple.com/us/app/vital-track-peptide-glp-1/id6770797345](https://apps.apple.com/us/app/vital-track-peptide-glp-1/id6770797345) ;iTunes lookup(us / gb / ca / au)

- [vitaltracker.app/](https://vitaltracker.app/), [vitaltracker.app/support/](https://vitaltracker.app/support/)

- [optimalapps.ca/](https://optimalapps.ca/); app list for iTunes developer 1869164799

- Competitors: [peptidetracker.ai/](https://peptidetracker.ai/), [peptiq.io/peptide-apps](https://peptiq.io/peptide-apps), [lynkdose.com/blog/free-peptide-tracker-app/](https://lynkdose.com/blog/free-peptide-tracker-app/), [shotsyapp.com/](https://shotsyapp.com/), [finance.yahoo.com/healthcare/articles/peptide-tracker-launch…](https://finance.yahoo.com/healthcare/articles/peptide-tracker-launches-google-play-210400869.html), [www.reddit.com/r/PeptidePathways/comments/1u18yaj/](https://www.reddit.com/r/PeptidePathways/comments/1u18yaj/)

- x-radar search for "vitaltracker" (0 posts in the last 60 days); TikHub search for "vitaltracker" (no relevant results)

This article was written by AI from public data and the data we collect daily. Numbers are sourced, and inferences are labeled.